UNSPSC 51384522: Dexketoprofen trometamol

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H14O3.C4H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N674F7L21E, chemically known as benzeneacetic acid, 3-benzoyl-.alpha.-methyl-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1), (.alpha.s)-, but more generally known as dexketoprofen trometamol, which bears US NIH Compound Identifier 177976.

European Medicines Agency schedules dexketoprofen trometamol or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07034MIG. Most nations, for tariff purposes, schedule dexketoprofen trometamol under HS 29183000. SMILES: C[C@@H](C1CCCC(C1)C(=O)C2CCCCC2)C(=O)O.C(C(CO)(CO)N)O.

UNSPSC 51384522 Dexketoprofen trometamol is a Commodity code that encompasses pharmaceutical active ingredients and finished-dose medications procured by state and local health agencies, though the recent opportunities posted under this code reflect a broader pharmaceutical and health product procurement activity than the code's name alone suggests. State and local governments use this code to source generic pharmaceuticals, over-the-counter products, and emergency medical supplies including naloxone and drug deactivation systems for community health programs, pharmacy benefit initiatives, and institutional healthcare operations. Soliciting bodies include state health and human services departments, county health agencies, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, and the Texas Health and Human Services Commission represent state-level aggregate buyers consolidating pharmaceutical procurement across multiple facilities and participating members.

Recent activity spans the Upper Midwest and South, with Minnesota (through MMCAP, which serves participating jurisdictions including Oregon), Texas, and Florida visible in the most recent opportunities. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with bids due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to solicit vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, signaling the state's interest in restructuring pharmacy benefit procurement outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with proposals due March 26, 2026, and contract effectiveness set for July 1, 2026; the RFP emphasizes price competitiveness (weighted at 75 percent of evaluation) and requires vendors to comply with cGMP, DSCSA, and FDA requirements, maintain relationships with at least two of three designated wholesalers, and pay a 3 percent administrative fee on all contract purchases.